.product_section .product_form, .product_gallery { opacity: 1; } .multi_select, form .select { display: block !important; } .image-element__wrap { display: none; }

May 28, 2026

The Complete Guide to CBD Cannabinoids: CBG, CBN, Delta-8, THCV, and More | PureCraft CBD

Medical Disclaimer | This article is for informational and educational purposes only. Cannabinoid supplements are not intended to diagnose, treat, cure, or prevent any disease or medical condition. PureCraft CBD products are broad-spectrum, zero-THC, and batch-verified at purecraftcbd.com/pages/faq. Individual results may vary.

Why Hemp Contains Over 100 Cannabinoids — and Why It Matters

If you have spent any time in the CBD space, you have encountered the acronym soup: CBG, CBN, THCV, CBC, Delta-8. Marketing copy deploys these terms liberally, often without explaining what they actually are, how they differ from CBD, or why they matter for the person buying a product. This guide cuts through that noise.

The hemp plant (Cannabis sativa L., < 0.3% THC) produces over 100 distinct cannabinoids, along with hundreds of terpenes and flavonoids. Most of these compounds exist in trace concentrations. A small subset — CBD, CBG, CBN, THCV, CBC, and Delta-8 — have accumulated enough research interest and commercial relevance to deserve serious attention. Each one has a distinct mechanism of action. Each interacts with the body's endocannabinoid system (ECS) differently. And each contributes something different to theentourage effect — the phenomenon where hemp's cannabinoids and terpenes produce greater benefits in combination than in isolation.

This pillar post covers all of them systematically: what each cannabinoid is, how it works mechanistically, what the research shows, whether it appears in PureCraft's products, and what it means for drug testing. The complete ECS foundation that makes all of this possible is covered inWhat Is the Endocannabinoid System? A Complete Guide. For a deeper mechanistic dive into CB1, CB2, FAAH, and retrograde signaling, seeHow the Endocannabinoid System Regulates Your Body: A Deep Dive.

CBD (Cannabidiol): The Foundation Cannabinoid

Primary Mechanisms: How CBD Works

CBD is the most extensively researched cannabinoid and the primary active ingredient inCBD Oil. Unlike THC — which binds directly to CB1 receptors in the brain, producing the 'high' associated with cannabis — CBD does not directly bind CB1. Instead, it modulates the ECS through multiple indirect pathways, each contributing to different aspects of its therapeutic profile:

• 5-HT1A serotonin receptor agonism:CBD activates 5-HT1A receptors in the amygdala and prefrontal cortex, reducing anxiety, lowering amygdala reactivity to threat stimuli, and producing anxiolytic effects without sedation. This is the mechanism behind CBD's well-documented effects onCBD for Anxiety: The Complete 2026 Guide.

• CB2 receptor activation:CB2 receptors are concentrated in peripheral immune tissue, joint synovium, skin, bone, and gut. CBD's CB2 activation shifts macrophage phenotype from pro-inflammatory (M1) to anti-inflammatory (M2), reduces cytokine production, and drives the anti-inflammatory effects relevant toCBD for Pain: The Complete 2026 Guide,CBD for Inflammation: What the Science Actually Says, andCBD for Arthritis: The Complete Evidence-Based Guide.

• TRPV1 (capsaicin receptor) desensitization:TRPV1 receptors are pain and heat sensors in peripheral nerves and joint tissue. CBD desensitizes them, reducing nociceptive signal intensity — the mechanism behind CBD's topical analgesic applications.

• FAAH enzyme inhibition:FAAH (fatty acid amide hydrolase) is the enzyme that breaks down anandamide — the body's primary endocannabinoid. By inhibiting FAAH, CBD preserves elevated anandamide levels, which supports sleep quality, emotional tone, and attentional clarity. This is the mechanism behind the sleep applications inCBD+CBN Sleep Gummies.

•HPA axis modulation:CBD reduces the cortisol elevation associated with chronic stress — recalibrating the hypothalamic-pituitary-adrenal axis over 2–4 weeks of consistent daily use. This cumulative effect supports the anxiety, burnout, and sleep applications documented throughout the PureCraft blog.

Most Studied Applications

CBD's clinical evidence base is the strongest of any cannabinoid. Human studies support applications in: generalized anxiety disorder, social anxiety, PTSD, epilepsy (FDA-approved as Epidiolex), insomnia, chronic pain, inflammation, and a growing body of evidence in depression, cognitive aging, and cardiovascular health.CBD Oil 1000mg is PureCraft's flagship product — nano-optimized broad-spectrum CBD, zero-THC verified by batch-specificbatch-tested COA.

Why CBD Is the Broad-Spectrum Anchor

In PureCraft's broad-spectrum formula, CBD is the primary ingredient by concentration, but it doesn't work alone. The minor cannabinoids — CBG, CBN, CBC — and the hemp terpenes in the formula contribute their own mechanisms, amplifying and extending CBD's effects through the entourage effect. Understanding the minor cannabinoids is therefore not just academic curiosity — it explains whyCBD Oil works better than a CBD isolate product at the same milligram dose. SeeFull-Spectrum vs Broad-Spectrum vs CBD Isolate: The Complete Guide for the full broad-spectrum vs isolate comparison.

CBG (Cannabigerol): The Mother Cannabinoid

What CBG Is and How It's Produced

CBG has earned the nickname 'the mother cannabinoid' for good reason: it is the biosynthetic precursor from which all other cannabinoids are derived. In the young hemp plant, cannabigerolic acid (CBGA) is the primary compound produced. As the plant matures, enzymes convert CBGA into CBDA, THCA, and CBCA — the acidic precursors to CBD, THC, and CBC respectively. By harvest time, most CBGA has been converted, which is why CBG exists only in trace concentrations in mature hemp — typically less than 1% of the cannabinoid profile.

The scarcity of CBG in mature plants makes it more expensive to produce than CBD, which is why most broad-spectrum products contain only trace CBG. PureCraft's broad-spectrum formula retains the CBG present in the hemp extract rather than filtering it out — preserving the entourage effect contribution of this trace but biologically active compound.

CBG Mechanisms: How It Differs From CBD

CBG's mechanisms are distinct from CBD's in several important ways, making them complementary rather than redundant:

• α2-Adrenergic receptor agonism:CBG activates α2-adrenergic receptors, which regulate norepinephrine release. This is the mechanism that contributes to CBG's observed effects on intraocular pressure (relevant to glaucoma research) and may contribute to mild anxiolytic effects via the autonomic nervous system.

• 5-HT1A partial antagonism:Unlike CBD, which is a 5-HT1A agonist, CBG is a partialantagonist at 5-HT1A — meaning it has the opposite serotonergic direction. The functional implications of this are not fully understood, but it underscores that CBG and CBD are mechanistically distinct even where they share receptor targets.

• CB1 and CB2 partial agonism:CBG has modest direct binding affinity for both CB1 and CB2 receptors — unlike CBD, which does not directly bind either. At the trace concentrations present in broad-spectrum products, this contributes an additive CB2 anti-inflammatory effect alongside CBD's indirect CB2 activation.

• TRPV1 modulation:Like CBD, CBG modulates TRPV1 receptors, contributing to its analgesic and anti-inflammatory profile.

CBG Research: What Studies Show

CBG has attracted serious research attention across several application areas:

• Inflammatory bowel disease:Borrelli et al. (2013) demonstrated that CBG significantly reduced colon inflammation, weight loss, and colon shortening in a murine IBD model — outperforming CBD in the gut-specific context. The mechanism was identified as CB2 receptor activation in colonic tissue.

• Neuroprotection — Huntington's disease:Valdeolivas et al. (2015) showed that CBG was neuroprotective in a mouse model of Huntington's disease, reducing striatal neurotoxicity and improving motor function. The neuroprotective mechanism was attributed to CB1/CB2 receptor and PPARγ pathway activation.

• Antibacterial — MRSA:Farha et al. (2020) identified CBG as the most potent antibacterial compound in their cannabinoid screening study, showing activity against MRSA (methicillin-resistant Staphylococcus aureus) — including drug-resistant biofilm strains.

•Glaucoma — intraocular pressure:Early research showed CBG reduced intraocular pressure in animal models, with the α2-adrenergic mechanism proposed as the primary pathway. This potential application is preliminary and requires human confirmation.

SeeCBG: What Is It and What Does the Research Show?for the complete CBG deep dive.

CBN (Cannabinol): The Sleep Cannabinoid

How CBN Forms — CBD Oxidation Over Time

CBN is not synthesized directly by the hemp plant like CBD or CBG. Instead, it forms as THC oxidizes and degrades over time — when cannabis is exposed to heat, light, or air. This means CBN content increases as hemp material ages, and fresh hemp contains relatively little CBN. It can also form as CBD oxidizes, which is relevant for the broad-spectrum context. CBN is only mildly psychoactive — much less so than THC — and does not produce the intoxicating effects associated with delta-9 THC.

CBN's Sleep Mechanism: CB1 and Slow-Wave Architecture

CBN is often called 'the sleepy cannabinoid,' and the mechanism supports this characterization. CBN hasmild CB1 receptor agonism — the same receptor pathway through which THC produces sedation, but with significantly lower binding affinity and potency. In the brain regions that regulate slow-wave sleep (NREM stage 3), CB1 activation supports deeper sleep architecture and sleep onset.

In practical terms, this means CBN works on a different sleep mechanism than CBD.CBD Oil supports sleep through HPA recalibration (reducing cortisol and the anxiety that prevents sleep onset) and FAAH inhibition (preserving anandamide for sleep quality). CBN addsdirect CB1-mediated slow-wave sleep depth support— making the combination inCBD+CBN Sleep Gummiesmore comprehensive than either compound alone. The gummies formula also includes physiological-dose melatonin for circadian timing support — the third distinct sleep mechanism addressing the full sleep problem.

CBN Research: What We Know

CBN's research base is smaller than CBD's, and many of the claims made about it in the wellness space outrun the evidence. The honest summary:

•Early human pharmacology studies (Hollister, 1973) confirmed CBN is sedating when combined with THC, but the sedative effect of CBN alone is less well-established in isolated human trials

•Preclinical animal data (Murillo-Rodríguez et al., 2014) confirms CBN modulates the rat sleep-wake cycle via CB1 mechanisms, increasing total sleep time

•The 'CBN is 5x more sedating than THC' claim circulates frequently in wellness content — this appears to trace to a single 1975 study of CBN in combination with alcohol, and does not reflect isolated CBN's pharmacological profile

The practical evidence: many users ofCBD+CBN Sleep Gummies report meaningful improvement in sleep depth and next-morning restedness — consistent with CBN's CB1-mediated slow-wave mechanism, even where isolated human RCT data is limited. SeeCBN for Sleep: The Science Behind the Sleepy Cannabinoid for the complete CBN sleep analysis.

THCV (Tetrahydrocannabivarin): The Appetite and Focus Cannabinoid

CB1 Antagonism at Low Doses — The Counterintuitive Mechanism

THCV (tetrahydrocannabivarin) is structurally similar to THC but has a propyl rather than pentyl side chain — a small molecular difference that produces dramatically different pharmacological behavior. Atlow doses, THCV acts as aCB1 receptor antagonist — blocking rather than activating the receptor. This is the opposite of what THC does. The practical implications are significant:

•Appetite suppression:CB1 agonism produces the well-known 'munchies' of THC. CB1 antagonism produces the opposite — appetite reduction. Wargent et al. (2013) demonstrated that THCV improved insulin sensitivity and reduced fasting glucose in obese mouse models, suggesting metabolic health benefits aligned with this appetite-suppressing mechanism.

•Anti-psychotic and anxiolytic potential:CB1 antagonism at low doses may produce the opposite of THC's anxiety-inducing effects at high doses. This makes THCV of interest in schizophrenia and anxiety research, where CB1 overactivation may contribute to symptom burden.

• Athigh doses, THCV reverses to CB1 agonism and can produce mild psychoactive effects similar to THC. Standard broad-spectrum products contain only trace THCV, making this dose-dependent psychoactivity irrelevant at normal use levels — but worth flagging for completeness.

THCV Research: Metabolic Health and Bone

Beyond the obesity model, THCV has shown preliminary evidence for bone health applications — CB2 receptors are expressed in bone tissue, and THCV's CB2 agonism may support osteoblast activity similarly to CBD's documented bone-relevant mechanisms (seeCBD and Bone Health: What Seniors Should Know). The diabetes application is covered inCBD for Type 2 Diabetes: What You Need to Know. THCV research is earlier-stage than CBG or CBN and primarily preclinical — human trial data is limited. SeeTHCV: What Is It and What Does the Research Show? for the dedicated deep dive.

CBC (Cannabichromene): The Inflammation and Mood Cannabinoid

CBC's Unique Mechanism: TRP Channels, Not CB Receptors

CBC is one of the most pharmacologically interesting minor cannabinoids because it achieves its effects through acompletely different receptor family from CBD and CBG. Rather than acting primarily through CB1 or CB2 receptors, CBC activatesTRPV1 (transient receptor potential vanilloid 1) and TRPA1 channels — pain and temperature sensors distributed throughout peripheral nerves, the gut, and inflammatory tissue. CBC also inhibits the reuptake of endocannabinoids (anandamide and 2-AG), allowing them to remain active at their receptors longer — amplifying the endocannabinoid signal without binding cannabinoid receptors directly.

This non-CB1/CB2 mechanism means CBC is unlikely to produce psychoactive effects regardless of dose — it simply doesn't activate the same brain receptor system that THC and high-dose CBN engage.

CBC Research: Neurogenesis, Inflammation, and Mood

•Neurogenesis:El-Alfy et al. (2010) showed that CBC and CBD, when combined, produced greater antidepressant-like effects in animal models than either compound alone — suggesting synergistic mood effects. The proposed mechanism involves CBC's indirect support of adult neurogenesis in the hippocampus via its endocannabinoid reuptake inhibition.

•Anti-inflammatory:Cascio et al. (2010) identified CBC as 'a highly potent endocannabinoid reuptake inhibitor,' with the resulting elevated anandamide levels producing anti-inflammatory effects via CB2. This places CBC's anti-inflammatory contribution in the broad-spectrum formula alongside — not in competition with — CBD's CB2 activation.

•Entourage amplification:Because CBC elevates circulating anandamide levels, it amplifies the effects of every other ECS-active compound in the formula — including CBD's FAAH inhibition. The combination of FAAH inhibition (CBD) plus endocannabinoid reuptake inhibition (CBC) produces greater anandamide preservation than either mechanism alone.

SeeCBC: The Inflammation and Mood Cannabinoid Explained for the dedicated CBC analysis.

Delta-8 THC: The Milder Psychoactive Cannabinoid

How Delta-8 Differs From Delta-9 — Pharmacology and Potency

Delta-8 THC (delta-8-tetrahydrocannabinol) is a structural isomer of delta-9 THC — same molecular formula, different arrangement of atoms. The double bond in the carbon chain sits at the 8th rather than 9th position, producing a compound with similar but weaker CB1 agonism than delta-9. The practical difference: delta-8 is psychoactive but reportedly less intensely so than delta-9, with a lower ceiling effect and somewhat different side effect profile (less anxiety, less paranoia at equivalent doses).

Delta-8 is important to discuss in a cannabinoid guide primarily because of what it is NOT:it is not a minor cannabinoid that occurs naturally in meaningful concentrations in hemp. Delta-8 exists in trace amounts in the hemp plant — commercially available delta-8 products are made by chemically converting CBD into delta-8 via acid-catalyzed isomerization. This synthetic conversion process is the source of most of delta-8's safety concerns: the reaction can produce unwanted byproducts and intermediary compounds that are not well-characterized for safety.

Safety Concerns and FDA Position

The FDA has issued multiple consumer warnings about delta-8 products. Between 2021 and 2022, the FDA received 104 adverse event reports related to delta-8 THC — including hallucinations, vomiting, tremor, anxiety, dizziness, confusion, and loss of consciousness. The FDA's position is that delta-8 products have not been evaluated or approved and may be marketed in ways that put public health at risk.

The contamination risk is compounded by the lack of quality standards in the delta-8 market. Unlike the CBD industry, which has developed a voluntary COA testing infrastructure (seeHow to Read a CBD Certificate of Analysis (COA): A Step-by-Step Guide), many delta-8 products are sold without adequate testing for residual acids, reaction byproducts, or potency accuracy.

Pure Crafts CBD Oil's broad-spectrum formula does not include delta-8 THC. PureCraft's product philosophy is built on zero-THC verification via third-partybatch-tested COA — not merely meeting the 0.3% legal threshold but confirming 0.00% THC at the batch level. Delta-8 is psychoactive by mechanism, carries unresolved safety concerns, and represents exactly the category of unregulated chemical modification that the COA testing framework exists to screen against. SeeDelta-8 THC vs CBD: What's the Difference and Which Is Safer? for the complete delta-8 vs CBD comparison.

Delta-9 THC (Hemp-Legal) and the Drug Testing Risk

The 0.3% Threshold — Legal but Not Drug-Test Safe

Hemp is legally defined in the US as cannabis containing less than 0.3% delta-9 THC by dry weight. Full-spectrum CBD products contain this trace THC as part of their cannabinoid profile. At a single use, 0.3% THC in a standard serving size is unlikely to produce psychoactive effects or cause an immediate positive drug test. The problem is accumulation: with daily full-spectrum use, delta-9 THC can accumulate in fat tissue to levels that produce a positive urine drug screen.

This is the primary reason PureCraft uses abroad-spectrum rather than full-spectrum formula: the zero-THC approach eliminates the drug testing risk while retaining all the minor cannabinoids (CBG, CBN, CBC) and terpenes that contribute to the entourage effect. You get the entourage benefit without the THC accumulation risk. Every batch is verified at 0.00% THC viabatch-tested COA. SeeCBD and Drug Testing: Will CBD Show Up on a Drug Test? for the complete drug testing guide andFull-Spectrum vs Broad-Spectrum vs CBD Isolate: The Complete Guide for the full-spectrum vs broad-spectrum comparison.

Terpenes: The Aromatic Amplifiers of the Entourage Effect

Terpenes are not cannabinoids — they are the aromatic compounds responsible for the distinctive smell of hemp and cannabis. But several hemp terpenes have documented pharmacological activity that contributes meaningfully to the entourage effect.Beta-caryophylleneis the most pharmacologically significant: Gertsch et al. (2008) identified it as the only terpene with direct cannabinoid receptor binding affinity — specifically a CB2 agonist, making it a 'dietary cannabinoid' that contributes CB2 anti-inflammatory effects alongside CBD.Linaloolactivates GABA-A receptors for anxiolytic effects.Myrcene has sedating properties via GABA-A modulation.Limonene modulates 5-HT1A for mood and anxiety effects.

CBD Oil's broad-spectrum formula retains the hemp plant's natural terpene profile, preserving these contributions. CBD isolate products — which strip everything except CBD — lose the terpene contribution entirely, producing a pharmacologically narrower product. SeeTerpenes and CBD: How Hemp Terpenes Enhance the Entourage Effect for the complete hemp terpene guide.

The Entourage Effect: Why Cannabinoids Work Better Together

The entourage effect — first proposed by Mechoulam and Ben-Shabat in 1998 — describes the phenomenon where the combined action of cannabinoids and terpenes produces greater therapeutic benefit than any single compound in isolation. The mechanism is not simply additive: the compounds modulate each other's receptor interactions, compete for the same metabolizing enzymes, and produce downstream effects that individual compounds cannot.

Russo's landmark 2011 review 'Taming THC' formalized the entourage concept, demonstrating through both mechanistic analysis and clinical observations that the phytocannabinoid-terpenoid combination explains much of why whole-plant cannabis preparations outperformed synthetic THC in clinical settings. Pamplona et al. (2018) found that CBD-rich whole-plant extracts required significantly lower doses than purified CBD to achieve equivalent seizure reduction in pediatric epilepsy — direct human evidence that the entourage effect has clinical magnitude, not just pharmacological elegance.

Combination	What Each Does	Synergy Type	Evidence Base
CBD + CBN	CBD: HPA recalibration, 5-HT1A anxiety; CBN: CB1 slow-wave sleep	Additive — different sleep pathways	PureCraft Sleep Gummies; Murillo-Rodríguez 2014
CBD + CBG	CBD: systemic anti-inflammatory; CBG: gut CB2 + antibacterial	Complementary — different tissue targets	Borrelli 2013; Izzo 2009
CBD + CBC	CBD: 5-HT1A, TRPV1; CBC: TRPA1, endocannabinoid reuptake inhibition	Additive — broader TRP channel coverage	Cascio 2010; El-Alfy 2010
CBD + β-caryophyllene (terpene)	CBD: systemic ECS; β-caryophyllene: direct CB2 dietary agonist	Additive CB2 activation from non-cannabinoid pathway	Gertsch 2008 — β-caryophyllene is the only terpene with direct CB receptor binding
CBD + linalool (terpene)	CBD: 5-HT1A, HPA; linalool: GABA-A, anxiolytic	Additive anxiolytic — different neurotransmitter targets	Guimarães-Santos 2011
Full-spectrum (all cannabinoids + terpenes)	Collective — all mechanisms operating simultaneously	True entourage — synergistic, not merely additive	Ben-Shabat 1998; Russo 2011; Pamplona 2018

The table above makes the key point:each cannabinoid in PureCraft's broad-spectrum formula contributes through a different mechanism. CBD's 5-HT1A and FAAH. CBG's α2-adrenergic and gut CB2. CBN's mild CB1 sedation. CBC's TRPA1 and endocannabinoid reuptake. Beta-caryophyllene's direct CB2 binding. This multi-mechanism coverage explains the clinical observation that broad-spectrum products — at the same CBD milligram dose — produce different and often superior results compared to CBD isolate.

Cannabinoid Comparison Table: CBD vs CBG vs CBN vs THCV vs CBC vs Delta-8

Cannabinoid	Primary Mechanism	Psychoactive?	Best For	Found in PureCraft?	Drug Test Risk	Key Research
CBD	5-HT1A, CB2, TRPV1, FAAH inhibition	No	Anxiety, pain, sleep, inflammation, general wellness	Yes — primary ingredient	None (zero-THC verified)	Blessing 2015; Shannon 2019; Hammell 2016
CBG	α2-adrenergic, CB1/CB2 partial agonist, 5-HT1A partial antagonist	No	Gut inflammation, antibacterial, neuroprotection	Yes — in broad-spectrum formula	None	Borrelli 2013; Valdeolivas 2015; Farha 2020
CBN	CB1 agonism (mild), GABA-A modulation	Mildly sedating at high doses	Sleep architecture, slow-wave depth	Yes — in Sleep Gummies	None documented	Hollister 1973; Murillo-Rodríguez 2014
THCV	CB1 antagonist (low dose) / agonist (high dose)	Mildly at high doses	Appetite suppression, metabolic health, blood sugar	Trace levels possible in broad-spectrum	Possible at high doses — check COA	Wargent 2013; Riedel 2009
CBC	TRPV1, TRPA1, endocannabinoid reuptake inhibition — no CB1/CB2	No	Anti-inflammatory, neurogenesis, mood	Yes — in broad-spectrum formula	None	Cascio 2010; El-Alfy 2010
Delta-8 THC	Partial CB1 agonist	Yes — milder than Delta-9	N/A — PureCraft does not use Delta-8	No — PureCraft does not use Delta-8	Yes — will cause positive drug test	LoParco 2023; Kruger 2022
Delta-9 THC (hemp)	Full CB1 agonist	Yes — at meaningful doses	Entourage effect at trace levels	Trace (<0.3%) in broad-spectrum	Yes — accumulates with repeated full-spectrum use	Russo 2011
Terpenes (e.g. β-caryophyllene)	CB2 agonism (β-caryophyllene); GABA-A (linalool); varied	No	Entourage effect, targeted anxiolytic/sedative/anti-inflammatory	Yes — broad-spectrum retains hemp terpenes	None	Gertsch 2008; Russo 2011

The table makes the PureCraft product philosophy concrete:CBD Oil is broad-spectrum (CBG, CBN, CBC, terpenes — no Delta-8, 0.00% THC) because this combination maximizes entourage benefit while eliminating the drug testing risk and psychoactivity of THC-containing formulas. Every batch is independently verified by an ISO-accredited third-party laboratory — thebatch-tested COA is accessible atpurecraftcbd.com/pages/faq.

PureCraft's Broad-Spectrum Formula: What's In It and Why

PureCraft'sCBD Oil andCBD+CBN Sleep Gummies are formulated on a broad-spectrum hemp extract — meaning:

•CBD:Primary ingredient. Verified at label-claim potency on every batch COA

• CBG:Trace concentrations retained from the hemp plant. Contributes gut CB2 anti-inflammatory and neuroprotective effects

• CBN:Present in the broad-spectrum oil in trace amounts; concentrated specifically inCBD+CBN Sleep Gummies for sleep architecture support alongside physiological-dose melatonin

•CBC:Retained in broad-spectrum extract. Contributes TRPA1/TRPV1 anti-inflammatory and endocannabinoid reuptake inhibition

• Hemp terpenes:Retained in the CO2 extraction process. Includes beta-caryophyllene (direct CB2 agonism), linalool (GABA-A anxiolytic), myrcene (sedating), and others

•Zero THC (0.00%):Verified on every batch COA. No delta-8 THC, no delta-9 THC. Safe for drug-tested athletes, employees, and anyone requiring THC-free verification

The nano-optimization of PureCraft's formula — encapsulating cannabinoids in lipid nanoparticles for enhanced bioavailability — means that each milligram of CBD (and each trace cannabinoid) is more efficiently absorbed than standard oil-based CBD. SeeNano CBD vs Regular CBD: What's the Difference and Does It Matter?for the bioavailability comparison.

The result: consistent, effective cannabinoid delivery at lower milligram doses than non-nano-optimized competitors.

Frequently Asked Questions

What are minor cannabinoids?

Minor cannabinoids are the cannabinoids present in the hemp plant in concentrations below CBD and THC. The primary minor cannabinoids with documented pharmacological activity are CBG (cannabigerol), CBN (cannabinol), THCV (tetrahydrocannabivarin), and CBC (cannabichromene). Each has a distinct mechanism of action and contributes differently to hemp extract's effects. In PureCraft's broad-spectrumCBD Oil, trace concentrations of these minor cannabinoids are retained alongside CBD, contributing to the entourage effect.

What is the difference between CBD and CBG?

CBD and CBG are structurally and mechanistically distinct cannabinoids. CBD works primarily through 5-HT1A serotonin receptors (anxiety), CB2 receptors (inflammation), TRPV1 (pain), and FAAH inhibition (sleep/mood). CBG works through α2-adrenergic receptors (intraocular pressure, autonomic regulation), CB1/CB2 partial agonism, and shows particularly strong effects in gut-specific CB2 applications (IBD research) and antibacterial activity. They are complementary rather than competitive — different mechanisms addressing different aspects of wellness. Both are present inCBD Oil's broad-spectrum formula.

Does CBN make you sleepy?

CBN has mild CB1 receptor activity that supports slow-wave sleep architecture — the deep, restorative stage of sleep. The degree of sedation from CBN alone (without THC) is debated in the research literature: some studies suggest modest sedation, while others indicate CBN's sedating reputation derives partly from its historical co-occurrence with THC in aged cannabis. In PureCraft'sCBD+CBN Sleep Gummies, CBN is combined with CBD (HPA recalibration) and physiological-dose melatonin (circadian timing) to address multiple sleep mechanisms simultaneously. Most users report improved sleep depth and quality rather than acute sedation or grogginess.

What does THCV do?

THCV is a CB1 antagonist at low doses — producing the opposite of THC's appetite-stimulating effect by blocking CB1 rather than activating it. Research has demonstrated appetite suppression and improved insulin sensitivity in animal models. THCV may also have anxiolytic effects through CB1 antagonism. At higher doses, THCV reverses to CB1 agonism and can produce mild psychoactive effects. In broad-spectrum hemp products, THCV exists only in trace concentrations — contributing potential metabolic benefits without meaningful psychoactivity risk.

What is CBC cannabinoid used for?

CBC (cannabichromene) works through TRPV1 and TRPA1 channels — not CB1/CB2 receptors — and also inhibits endocannabinoid reuptake, elevating circulating anandamide. Research applications include anti-inflammatory effects, neurogenesis support (relevant to depression research), and entourage amplification in combination with CBD. CBC is non-psychoactive regardless of dose. InCBD Oil's broad-spectrum formula, trace CBC contributes to the combined anti-inflammatory and neurogenic profile of the formula. SeeCBC: The Inflammation and Mood Cannabinoid Explained.

Is Delta-8 THC legal?

Delta-8 THC occupies a legally uncertain position. It is not explicitly scheduled federally in the United States, which some interpret as legal under the 2018 Farm Bill (which legalized hemp derivatives). However, at least 20 states have explicitly banned or restricted delta-8, the FDA has issued multiple warnings about delta-8 products, and the DEA has suggested delta-8 produced from CBD conversion should be classified as a controlled substance. The legal landscape is actively evolving. PureCraft does not use delta-8 in any product and recommends avoiding unregulated delta-8 products given the safety and legal uncertainty.

What is the entourage effect?

The entourage effect is the phenomenon where cannabinoids and terpenes produce greater therapeutic benefit in combination than in isolation. Proposed by Mechoulam and Ben-Shabat (1998) and elaborated by Russo (2011), the entourage effect explains why whole-plant broad-spectrum extracts — which retain minor cannabinoids and terpenes alongside CBD — often outperform CBD isolate at equivalent milligram doses. The mechanism involves synergistic receptor interactions, enzyme competition, and downstream signaling that isolated compounds cannot replicate.Full-Spectrum vs Broad-Spectrum vs CBD Isolate: The Complete Guidecovers the full-spectrum vs broad-spectrum vs isolate comparison, including the drug testing implications.

How many cannabinoids are in hemp?

The hemp plant produces over 100 identified cannabinoids, though the vast majority exist in concentrations too low to have meaningful pharmacological relevance at typical product use levels. The cannabinoids with the most research attention and commercial relevance are CBD, CBG, CBN, THCV, CBC, delta-8 THC, and delta-9 THC. Dozens of other cannabinoids — CBDV, CBGV, CBDVA, CBL, and others — have been identified but remain poorly characterized in terms of human pharmacology.

Does broad-spectrum CBD contain CBG and CBN?

It depends on the extraction process and whether the manufacturer filters the extract. PureCraft's broad-spectrumCBD Oil retains the natural minor cannabinoid profile of the hemp plant — including trace CBG, CBN, and CBC — which is verified on the batch-specificbatch-tested COA accessible atpurecraftcbd.com/pages/faq. Not all broad-spectrum products retain these minor cannabinoids; some manufacturers filter them out or use CBD isolate blended back into a carrier oil, which would not contain CBG or CBN. The COA is the only reliable way to verify what a product actually contains.

Which cannabinoid is best for sleep?

Different cannabinoids address different sleep mechanisms. CBD (via HPA recalibration and FAAH inhibition) addresses cortisol and anxiety-driven sleep disruption — the most common mechanism of modern insomnia. CBN (via mild CB1 activation) supports slow-wave sleep architecture depth. Physiological-dose melatonin signals circadian timing. PureCraft'sCBD+CBN Sleep Gummies combine all three to address the full sleep problem: CBD for the cortisol-anxiety component, CBN for slow-wave depth, and physiological-dose melatonin for circadian timing. No single cannabinoid addresses all three mechanisms — the combination is the most complete sleep protocol.

Which cannabinoid is best for inflammation?

CBD has the strongest and broadest anti-inflammatory evidence, working through CB2 receptor activation that modulates cytokine production in peripheral immune tissue, joint synovium, skin, and gut. CBG adds gut-specific CB2 anti-inflammatory effects (particularly relevant for IBD) and direct antibacterial activity. CBC contributes through TRPV1/TRPA1 and endocannabinoid reuptake inhibition, which elevates anandamide's CB2 anti-inflammatory activity. Beta-caryophyllene adds direct CB2 agonism as a terpene. In PureCraft's broad-spectrumCBD Oil, all of these mechanisms operate simultaneously — this is the strongest argument for broad-spectrum over isolate for anti-inflammatory applications.

What cannabinoids are in PureCraft's CBD Oil?

CBD Oil is a broad-spectrum hemp extract containing: CBD (primary ingredient at verified label-claim potency), trace CBG, trace CBN, trace CBC, trace THCV (possible in broad-spectrum), and hemp terpenes including beta-caryophyllene, linalool, myrcene, limonene, and others. The product contains 0.00% THC — no delta-8, no delta-9 — verified on every batch by an ISO-accredited third-party laboratory. The full cannabinoid panel is listed on the batch-specificbatch-tested COA atpurecraftcbd.com/pages/faq.

The Bottom Line: Why the Cannabinoid Profile Matters

The CBD market has spent years fixating on milligrams. How many milligrams per serving? Per bottle? The cannabinoid profile matters as much as the concentration — because CBG, CBN, CBC, and terpenes are not marketing buzzwords. They are pharmacologically distinct compounds with documented mechanisms that contribute materially to what a broad-spectrum product does in the body.

Understanding the cannabinoid profile helps you make better product decisions, set accurate expectations, and understand whyCBD Oil (broad-spectrum, nano-optimized, zero-THC, minor cannabinoids retained) performs differently from an isolate product at the same milligram dose. The entourage effect is real. The minor cannabinoids are real. And the COA that verifies what's actually in each batch is the only reliable way to know what you're actually consuming.

Explore the dedicated deep dives:CBG: What Is It and What Does the Research Show? |CBN for Sleep: The Science Behind the Sleepy Cannabinoid |THCV: What Is It and What Does the Research Show? |CBC: The Inflammation and Mood Cannabinoid Explained |Delta-8 THC vs CBD: What's the Difference and Which Is Safer? |Terpenes and CBD: How Hemp Terpenes Enhance the Entourage Effect.PureCraft CBD Oil 1000mg — nano-optimized, broad-spectrum, 0.00% THC,batch-tested COA.browse all PureCraft CBD products.

Medical Disclaimer | This article is for informational and educational purposes only. Cannabinoid supplements are not intended to diagnose, treat, cure, or prevent any disease or medical condition. PureCraft CBD products are not FDA-evaluated for medical use. Individual results may vary. Consult a qualified healthcare provider before beginning any new supplement regimen.